CSNK1D and amyotrophic lateral sclerosis: Pharmacological modulation of CSNK1δ/ε has been reported to have beneficial impacts in ALS, FTD, and PD neurodegenerative disease phenotypes in vivo (Salado et al., 2014; Alquezar et al., 2016; Morales-Garcia et al., 2017).